Hematopoiesis News Volume 14.45 | Nov 14 2023

November 14, 2023

2023-11-14 | HN 14.45

Hematopoiesis News by STEMCELL Technologies

Vol. 14.45 – 14 November, 2023

TOP STORY

First in Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma

48 patients with chronic lymphocytic leukemia, B-cell non-Hodgkin lymphoma, or Waldenstrom’s macroglobulinemia, relapsed/refractory after ≥two prior therapies were enrolled in the open-label, single-arm, Phase I MK-1026-001 study to receive nemtabrutinib 5 mg to 75 mg once-daily in 28-day cycles.
[Cancer Discovery]

Abstract

Activate, expand & differentiate your cells with cytokines, chemokines, and growth factors. Click to request a sample.

PUBLICATIONSRanked by the impact factor of the journal

Regulation of Lymphoid-Myeloid Lineage Bias through Regnase-1/3-Mediated Control of Nfkbiz

Researchers showed that mRNA decay factors Regnase-1 and Regnase-3 were essential for determining lymphoid fate and restricting myeloid differentiation in hematopoietic stem and progenitor cells.
[Blood]

Abstract

GPIbα-Filamin a Interaction Regulates Megakaryocyte Localization and Budding during Platelet Biogenesis

Investigators generated a mouse model expressing either human wild-type glycoprotein Ibα (GPIbα) or a Filamin A-binding mutant and lacking endogenous mouse GPIbα.
[Blood]

Abstract

SRCAP Mutations Drive Clonal Hematopoiesis through Epigenetic and DNA Repair Dysregulation

Researchers showed that SRCAP mutations confer a selective advantage in human cells and in mice upon treatment with the anthracycline-class chemotherapeutic doxorubicin and bone marrow transplantation.
[Cell Stem Cell]

Full Article Graphical Abstract

A Transcriptional Network Governing Ceramide Homeostasis Establishes a Cytokine-Dependent Developmental Process

Investigators discovered that the hematopoietic transcription factor GATA1 established ceramide homeostasis during erythroid differentiation by regulating genes encoding sphingolipid metabolic enzymes
[Nature Communications]

Full Article

Stem Cell–Like Reprogramming Is Required for Leukemia-Initiating Activity in B-ALL

Researchers used the PAX5::ELN oncogenic model to demonstrate a causal link between the differentiation blockade, the self-renewal, and the emergence of pre-leukemic stem cells.
[Journal of Experimental Medicine]

Abstract

CLINICAL RESEARCH

Targeting Hyperactive Platelet-Derived Growth Factor Receptor-β Signaling in T Cell Acute Lymphoblastic Leukemia and Lymphoma

The authors reported a novel MYH9::PDGFRB fusion in aT cell lymphoblastic lymphoma patient and demonstrated that this fusion product was constitutively active and sufficient to drive oncogenic transformation in vitro and in vivo.
[Haematologica]

Abstract

Explore this validated protocol for high-efficiency CRISPR-Cas9 gene editing of Human Primary T Cells.

REVIEWS

Hematopoietic Stem Cells through the Ages: A Lifetime of Adaptation to Organismal Demands

The authors describe central features of HSC regulation during ontogeny to contextualize how adaptive responses over the life of the organism ultimately form the basis for HSC functional degradation with age.
[Cell Stem Cell]

Abstract

Efficacy and Safety of Eltrombopag in Chinese Patients with Refractory or Relapsed Severe Aplastic Anemia

The Phase II multicenter trial investigated the efficacy and safety of eltrombopag in 20 adult Chinese patients with refractory or relapsed severe aplastic anemia.
[Scientific Reports]

Full Article

INDUSTRY AND POLICY NEWS

US
Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Breyanzi (Lisocabtagene Maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Bristol Myers Squibb announced that the FDA has accepted the supplemental Biologics License Application for Breyanzito to expand its current indication to include the treatment of adult patients with relapsed or refractory CLL or SLL who received a prior Bruton tyrosine kinase inhibitor and B cell lymphoma 2 inhibitor.
[Bristol Myers Squibb]

Press Release

FEATURED EVENT

Hematopoiesis News Volume 14.45 | Nov 14 2023

First in Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma

Regulation of Lymphoid-Myeloid Lineage Bias through Regnase-1/3-Mediated Control of Nfkbiz

GPIbα-Filamin a Interaction Regulates Megakaryocyte Localization and Budding during Platelet Biogenesis

SRCAP Mutations Drive Clonal Hematopoiesis through Epigenetic and DNA Repair Dysregulation

A Transcriptional Network Governing Ceramide Homeostasis Establishes a Cytokine-Dependent Developmental Process

Stem Cell–Like Reprogramming Is Required for Leukemia-Initiating Activity in B-ALL

Targeting Hyperactive Platelet-Derived Growth Factor Receptor-β Signaling in T Cell Acute Lymphoblastic Leukemia and Lymphoma

Hematopoietic Stem Cells through the Ages: A Lifetime of Adaptation to Organismal Demands

Efficacy and Safety of Eltrombopag in Chinese Patients with Refractory or Relapsed Severe Aplastic Anemia

US
Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Breyanzi (Lisocabtagene Maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Cell Therapy for Autoimmune Disease Summit

> See All Events

Postdoctoral Fellow – Functional Genomics

Laboratory Director – Biobank

Postdoctoral Scientist – Cancer Research Cluster

Research Associate – Hematology & Cellular Therapy

Postdoctoral Associate – Immune Cells in Blood Diseases and GvHD

> See All Jobs